STOCK TITAN
  1. Home
  2. News
  3. LABP

Landos Biopharma Inc - LABP STOCK NEWS

Welcome to our dedicated news page for Landos Biopharma (Ticker: LABP), a resource for investors and traders seeking the latest updates and insights on Landos Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Landos Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Landos Biopharma's position in the market.

News
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) to acquire Landos Biopharma, Inc. (NASDAQ: LABP) for a total of $212.5 million to advance the development of NX-13, a first-in-class, oral NLRX1 agonist for the treatment of ulcerative colitis. The acquisition aims to fill a therapeutic gap in autoimmune diseases, with AbbVie recognizing the potential of NX-13 in addressing the needs of patients with ulcerative colitis and Crohn’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
173.31%
Tags
acquisition
-
News
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
Rhea-AI Summary
Landos Biopharma, Inc. (LABP) reports financial results for Q4 2023, with sufficient cash to fund operations until mid-2025. The company is focused on developing novel oral medicines for autoimmune diseases, particularly the NX-13 clinical program for ulcerative colitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.73%
Tags
earnings
-
News
Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation
Rhea-AI Summary
Landos Biopharma, a clinical-stage biopharmaceutical company (NASDAQ: LABP), announced that six abstracts were accepted for poster presentation at the 19th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO). The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69. The company has two novel targets anchoring libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications, including the clinical stage program NX-13 for ulcerative colitis (UC). NX-13 is currently in a Phase 2 proof-of-concept trial (NEXUS: NCT05785715) to evaluate the safety, efficacy and pharmacokinetics in patients with moderate to severe UC. The Company expects to report topline results in the fourth quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences
News
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis
Rhea-AI Summary
Landos Biopharma, Inc. (LABP) announced promising results for the NX-13 Phase 1b trial in patients with ulcerative colitis (UC). The drug demonstrated early signs of rapid symptomatic relief and endoscopic improvement, with top-line readout for the ongoing NEXUS Phase 2 trial expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.42%
Tags
clinical trial
-
News
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
Rhea-AI Summary
Landos Biopharma, Inc. (NASDAQ: LABP) remains on track with the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis, with top-line results planned for Q4 2024. The company also announced sufficient cash to fund operations into the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.49%
Tags
earnings
-
News
Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting
Rhea-AI Summary
Landos Biopharma to present additional findings from Phase 1b study of NX-13 for ulcerative colitis at ACG 2023 Annual Scientific Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
conferences
News
Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress
Rhea-AI Summary
Landos Biopharma presents new data on NX-13 in Phase 1b study for Ulcerative Colitis at UEG Week 2023 congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
conferences clinical trial
-
News
Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells
Rhea-AI Summary
Landos Biopharma collaborates with KU Leuven and University Hospitals Leuven to investigate effects of NX-13 on epithelial cells in ulcerative colitis patients. NEXUS Phase 2 trial on track for Q4 2024 results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none
-
News
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
earnings
News
Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
conferences
Stock LABP logo
Landos Biopharma Inc

Nasdaq:LABP

LABP Rankings

#4520 Ranked by Market Cap
#1094 Ranked by Stock Gains
N/A Ranked by Dividends

LABP Stock Data

67.13M
1.32M
9.92%
48.96%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Blacksburg

About LABP

there is an unmet need for new treatments for autoimmune diseases that transform paradigms and clinical practice. landos will address that unmet clinical need. we know physicians are tired of settling for mediocre therapies for patients living with autoimmune disorders. with one first in class, oral therapy for inflammatory bowel disease (ibd) and its two clinical manifestations: crohn’s disease and ulcerative colitis, showing remarkable preclinical results and entering clinical trials, our team is poised to soon offer ibd patients a better way. the bottom line is this: patients deserve treatment options that are safer, more effective, and less disruptive to their lives. that is what drives landos scientists and our team each and every day.